Consumer Updates > FDA Acts to Reduce Harm from Opioid Drugs

FDA Acts to Reduce Harm from Opioid Drugs

The White House on Tuesday unveiled a multi-agency plan aimed at reducing the “epidemic” of prescription drug abuse in the U.S.—including an FDA-backed education program that zeros-in on reducing the misuse and misprescribing of opioids.

Gil Kerlikowske, director of the White House Office of National Drug Control Policy, says the plan—a collaborative effort involving agencies of the departments of Justice, Health and Human Services, Veterans Affairs, Defense, and others—provides a national framework for reducing prescription drug abuse and the diversion of prescription drugs for recreational use.

“The toll our nation’s prescription drug abuse epidemic has taken in communities nationwide is devastating,” says Kerlikowske. “We share a responsibility to protect our communities from the damage done by prescription drug abuse.”

Key elements of the plan—called Epidemic: Responding to America’s Prescription Drug Abuse Crisis—include:

.expansion of state-based prescription drug monitoring programs
.recommending convenient and environmentally responsible ways to remove unused medications
.from homes
.supporting education for patients and health care providers
.reducing the number of “pill mills” and doctor-shopping through law enforcement


FDA Opioid Strategy

In concert with the White House plan, the Food and Drug Administration (FDA) is announcing a new risk reduction program—called a Risk Evaluation and Mitigation Strategy—for all extended-release and long-acting opioid medications.

Opioids are synthetic versions of opium that are used to treat moderate and severe pain.

FDA experts say extended-release and long-acting opioids—including OxyContin, Avinza, Dolophine, Duragesic, and eight other brand names—are extensively misprescribed, misused, and abused, leading to overdoses, addiction, and even deaths across the United States. FDA says a 2007 survey revealed that more than half of opioid abusers got the drug from a friend or relative.

Opioids—such as morphine and oxycodone—are used to treat moderate and severe pain. Over the past few decades, drug makers have developed extended-release opioid formulas to treat people in pain over a long period.

The new REMS plan focuses primarily on: educating doctors about proper pain management, patient selection, and other requirements and improving patient awareness about how to use these drugs safely. As part of the plan, FDA wants companies to give patients education materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

FDA wants drug makers to work together to develop a single system for implementing the REMS strategies. Toward that goal, FDA is now notifying opioid makers that they must propose a REMS plan within 120 days.

Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, says this risk management strategy is designed to improve pain management, while preserving patient access to these needed medications.

“This will be an important step toward addressing what has become a critical public health problem,” she says.

Doctor training, patient counseling, and other risk reduction measures developed by opioid makers as part of the REMS are expected to become effective by early 2012. They will be required for various brand name products known under the generic names:

.hydromorphone
.oxycodone
.morphine
.oxymorphone
.methadone
.transdermal fentanyl
.transdermal buprenorphine


Widespread Problem

FDA estimates that more than 33 million Americans age 12 and older misused extended-release and long-acting opioids during 2007—up from 29 million just five years earlier. And in 2006, nearly 50,000 emergency room visits were related to opioids.

"Opioid drugs have benefit when used properly and are a necessary component of pain management for certain patients, but we know that they pose serious risks when used improperly—with serious negative consequences for individuals, families, and communities," says FDA Commissioner Margaret A. Hamburg, M.D. “The prescriber education component of this Opioid REMS balances the need for continued access to these medications with stronger measures to reduce their risks."

Although doctor training is not mandatory under the REMS plan, other federal agencies are working to get Congress to link mandatory physician training to the already required Drug Enforcement Administration registration number that doctors must have to prescribe controlled substances.

FDA will also require the risk management plan to include a way to determine if the education programs are helping to reduce problems associated with long-acting and extended-release opioids, as well as allowing patients who need opioids to get them.

FDA has had the power to request companies to develop REMS since 2007. The plans may also include medication guides and patient package inserts.

This article appears on FDA's Consumer Updates page4, which features the latest on all FDA-regulated products.

April 19, 2011

full-text:
Consumer Updates > FDA Acts to Reduce Harm from Opioid Drugs


For More Information:

- List of Long-Acting and Extended-Release Opioid Products Required to have an Opioid REMS5
Information by Drug Class > List of Long-Acting and Extended-Release Opioid Products Required to have an Opioid REMS


- Questions and Answers: FDA Requires a Risk Evaluation and Mitigation Strategy (REMS) for Long-Acting and Extended-Release Opioids6
Information by Drug Class > Questions and Answers: FDA Requires a Risk Evaluation and Mitigation Strategy (REMS) for Long-Acting and Extended-Release Opioids


Consumer Updates > Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D.
Consumer Updates > Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D.

EL BIRUNI: DIRECTORIO DE DOCUMENTOS EDITADOS EN ABRIL 2011 [*]

sábado 30 de abril de 2011
EL BIRUNI: DIRECTORIO DE DOCUMENTOS EDITADOS EN ABRIL 2011 [*]
CIENCIAS MÉDICAS NEWS
CIENCIAS MÉDICAS APLICADAS
RESEARCH & CLINICAL DEVELOPMENT

sábado 30 de abril de 2011
EL BIRUNI: DIRECTORIO DE DOCUMENTOS EDITADOS EN ABRIL 2011 [*]


GRUPO DE BLOGS SALUD EQUITATIVA

► Iniciado en enero de 2009:
http://elbiruniblogspotcom.blogspot.com
▲ CIENCIAS MÉDICAS NEWS

► Iniciado en abril de 2008:
http://saludequitativa.blogspot.com
▲ GESTIÓN EN SALUD PÚBLICA

► Iniciado en enero de 2009:
http://herenciageneticayenfermedad.blogspot.com
▲ CIENCIAS DE LA HERENCIA

Consultas acumuladas desde enero 2009 a la fecha: 344.453
Consultas totales conjuntas (todos los blogs): 1.560.245
Páginas consultadas desde el inicio de los blogs (3): > 9,5 millones

Discriminadas como sigue:
1. ESTADOS UNIDOS DE NORTEAMÉRICA: 53.926 [15,7%]
2. ARGENTINA: 47.720 [13,9%]
3. ESPAÑA: 45.879 [13,3%]
4. MÉXICO: 43.346 [12,6%]
5. COLOMBIA: 18.595 [ 5,4%]
6. PERÚ: 16.942 [ 4,9%]
7. VENEZUELA: 16.113 [ 4,7%]
8. CHILE: 10.980 [ 3,2%]
9. ECUADOR: 7.469 [ 2,2%]
10. INDIA.: 5.494 [ 1,6%]
11. LOS DEMÁS: 77.989 [22,6%]
Total de consultas: 344.453


Documentos del mes de ABRIL 2011: 665
Documentos acumulados en 2011: 2.636
Documentos editados desde el inicio del blog: 13.451


MUESTRA ESTADÍSTICA (de un día): (al 30 de abril de 2011)
Páginas vistas por países (según estadísticas blogger):
Estados Unidos 4.512
Alemania 1.145
España 656
México 338
Rusia 327
Francia 286
Colombia 225
Argentina 209
Canadá 238
Reino Unido 207
Irán 151


Archivo del blog
▼  2011 (2636)
▼  abril (665)
1. Fatal Human Case of WEE | CDC EID
2. Widespread Availability of Artemisinin Monotherapy...
3. Yersinia pestis DNA Sequences | CDC EID
4. Comparative effectiveness of white blood cell grow...
5. Hospital Survey on Patient Safety Culture: 2011 Us...
6. Risk of arrhythmic and nonarrhythmic death in pati...
7. Guidance for Industry: "Computer Crossmatch" (Comp...
8. Safety of Probiotics Used to Reduce Risk and Preve...
9. A. phagocytophilum Infection in Ticks | CDC EID
10. The Crab Hole Mosquito Blues | CDC EID
11. Tick-Borne Encephalitis Virus, Kyrgyzstan | CDC EI...
12. HIV/AIDS Update - Update to Fuzeon (enfuvirti​de) ...
13. Transmission of Zika Virus, Colorado | CDC EID
14. Tick-Borne Relapsing Fever Borreliosis, Rural Sene...
15. Novel BTV Serotype, Kuwait | CDC EID
16. Spotted Fever Group Rickettsiae | CDC EID
17. Multitarget Test in a Serosurvey of Dogs | CDC EID...
18. Bartonella spp. in Feral Pigs | CDC EID
19. R. parkeri in Gulf Coast Ticks, Virginia | CDC EID...
20. Division of Nutrition, Physical Activity, Overweig...
21. The Three Steps of Gluten-Free Self-Management
22. Accidents at Nuclear Power Plants and Cancer Risk ...
23. Type 1 Diabetes Studies: NIAID Type 1 Diabetes Cli...
24. Salmonella enterica Serotype Typhi with Nonclassic...
25. Vaccines and Related Biological Products Advisory ...
26. Study Highlights Arthritis' Toll on Quality of Lif...
27. Report Ranks Top Sources of Illness Related to Foo...
28. After Treatment for Precancerous Cervical Lesions,...
29. 'Urgent Need' for Research on Cancer Among Minorit...
30. Paramedics must avoid too much injury care: Medlin...
31. Flu Vaccine Appears Safe After Kidney Transplant: ...
32. Kids’ ‘screen time’ linked to early markers for ca...
33. ACC/AHA Issue First Clinical Guidance for Controll...
34. Death rates among those with high blood pressure d...
35. Transferring doctors to heart attack patients impr...
36. Being tall, obese may significantly increase risk ...
37. Thyroid Drugs May Raise Fracture Risk in Elderly: ...
38. Anyone Can Get Skin Cancer - National Cancer Insti...
39. Fish oil: MedlinePlus Supplements || Eskimo diseas...
40. Pharmacy Student Experiential Program > DDI Webina...
41. About the Center for Drug Evaluation and Research ...
42. Workers Memorial Day --- April 28, 2011
43. Occupational Highway Transportation Deaths --- Uni...
44. Nonfatal Occupational Injuries and Illnesses Among...
45. Prevalence of Obesity Among Adults with Arthritis ...
46. Rotavirus Surveillance --- Worldwide, 2009
47. County-Level Trends in Vaccination Coverage Among ...
48. Genetic evidence for Rift Valley fever outbreaks i...
49. An Efficient Method for Generating Poxvirus Recomb...
50. MTHFR 677C->T genotype is associated with folate a...
51. West Nile Virus Isolates, Italy, 2008–2009 | CDC E...
52. Genomic Characterization of Nipah Virus | CDC EID
53. Chikungunya Virus, Southeastern France | CDC EID
54. Dengue among Hospitalized Patients, United States ...
55. Hepatitis E Virus Strains, Czech Republic | CDC EI...
56. West Nile Virus, Greece | CDC EID
57. 5-minute screen identifies subtle signs of autism ...
58. NIH study finds Avastin and Lucentis are equally e...
59. NIGMS issues its first strategic plan for research...
60. Vitamin E helps diminish a type of fatty liver dis...
61. More U.S. women using "morning-after" pill: study:...
62. For egg-allergic kids, one-dose flu shot may be OK...
63. No Long-Term Effects Seen From Anesthesia in Infan...
64. Don't Blame Memory for Trouble Switching Tasks: Me...
65. Researchers Describe Gene Activity in Living Cells...
66. Genome.gov | 2011 News Feature: New user's guide a...
67. NIH researchers create comprehensive collection of...
68. New Gene Therapy Technique on Induced Pluripotent ...
69. WHO | New WHO report: deaths from noncommunicable ...
70. Awareness Day Social Media Late April 2011
71. CDC - NIIW Educational Resources - National Infant...
72. CDC Data & Statistics | Feature: CDC's Asthma Call...
73. Journal of Clinical Oncology | Volume 29, Issue 12...
74. Cetuximab Plus Irinotecan, Fluorouracil, and Leuco...
75. Diet-Induced Aortic Valve Disease in Mice Haploins...
76. Circadian variations of infarct size in acute myoc...
77. Outcomes of Sipuleucel-T Therapy: Disposition of C...
78. L. serrata Tongue Worm | CDC EID
79. Filariasis Caused by Pelecitus sp. Nematode | CDC ...
80. Filariasis Caused by Dirofilaria sp. Nematode | CD...
81. Babesiosis, Lower Hudson Valley, New York | CDC EI...
82. Streptococcus suis Serotype 2, Thailand | CDC EID
83. Experimental Infection of Ticks with R. rickettsii...
84. Travel-related Dengue Virus Infection | CDC EID
85. Oral Transmission of Atypical Scrapie | CDC EID
86. Evidence-Based Heart Attack Care Reduces Deaths: S...
87. Pediatricians Urge Better Protection From Chemical...
88. Antidepressants Work Overall, But Some Symptoms Ma...
89. CDC Features - Protect Yourself from MRSA
90. Intervention to Reduce Transmission of Resistant B...
91. Fitness and Frailty Predict Health | Medical News ...
92. Blood Pressure: Good News, but not Good Enough | M...
93. Out With the Old? Treating Fatty Liver Disease | M...
94. Health Literacy Linked to Survival | Medical News ...
95. National Guideline Clearinghouse | Pediatric gastr...
96. National Guideline Clearinghouse | Quick starting ...
97. National Guideline Clearinghouse | Contraceptive c...
98. National Guideline Clearinghouse | Contraception f...
99. National Guideline Clearinghouse | Guidelines for ...
100. National Guideline Clearinghouse | Gynecologic car...
101. National Guideline Clearinghouse | Antiphospholipi...
102. National Guideline Clearinghouse | Allergic Rhinit...
103. Association of CTNNB1 (β-Catenin) Alterations, Bod...
104. CDC - Blogs - Safe Healthcare – No, it is not ok t...
105. Common Painkillers May Blunt Antidepressants: Medl...
106. Experts Offer New Guidance for Blood Pressure Cont...
107. Pediatricians Urge Better Protection From Chemical...
108. Pituitary Disorders (for patients) | Source: Ameri...
109. LEOPARD syndrome - Genetics Home Reference
110. Mevalonate kinase deficiency - Genetics Home Refer...
111. Plasmodium knowlesi Malaria in Children | CDC EID
112. Molecular Epidemiology of Oropouche Virus | CDC EI...
113. F. tularensis holarctica, Sweden | CDC EID
114. Evolution of New Genotype of WNV in North America ...
115. Artesunate for Malaria in Travelers, Europe | CDC ...
116. NIMH · Study Reveals New Clues to How Depression M...
117. NIMH · Light Switches Brain Pathway On-and-Off to ...
118. Music Training May Help Keep Aging Brain Healthy: ...
119. It May Be Possible to Predict Bipolar Mood Swings:...
120. Stents: How new technology drives health costs: Me...
121. CDC - NIIW home page - National Infant Immunizatio...
122. National Guideline Clearinghouse | American Societ...
123. INFLUENZA A H1N1, CIRCULACIÓN - ALERTA DE OMS/OPS
124. National Guideline Clearinghouse | Dronedarone for...
125. National Guideline Clearinghouse | Etanercept, inf...
126. National Guideline Clearinghouse | Gefitinib for t...
127. National Guideline Clearinghouse | Imatinib for th...
128. National Guideline Clearinghouse | Rituximab for t...
129. National Guideline Clearinghouse | Tocilizumab for...
130. National Guideline Clearinghouse | Pediatric gastr...
131. Vector-borne Infections | CDC EID
132. Severe Imported Malaria, France | CDC EID
133. Pneumonic Plague Diagnosis, DRC | CDC EID
134. Free Webinars: The Fundamenta​ls of Accountabl​e C...
135. FDA Hepatitis Update - April 27, 2011 FDA Advisory...
136. Scientists Discover How Peppermint Soothes Gastric...
137. Nature and nurture key in bladder-control problems...
138. Some heart surgery patients skip statin therapy: M...
139. Mental Disorders Linked to Drug, Alcohol Abuse in ...
140. HIV Kids Growing Up Well, Study Finds: MedlinePlus...
141. Managing Chemoradiation Side Effects May Prolong S...
142. Nail Guns Often Sold Without Safety Advice: Study:...
143. Hospital Infection Raises Death Risk for Bowel Pat...
144. Research Activities, April 2011: Agency News and N...
145. Grandsons may be affected by old pregnancy drug: M...
146. Pregnant and Stressed May Mean Offspring Who Misbe...
147. Instruction for midwives lowers death rate for new...
148. Gene Could Hold Key to Muscle Repair - NIH Researc...
149. Broccoli Compound May Combat COPD - NIH Research M...
150. Cancer Burden Shifts for HIV-Infected Population -...
151. Deep-Vein Thrombosis of the Upper Extremities — NE...
152. Chest Compression–Only CPR by Lay Rescuers and Sur...
153. Arsenic For Leukemia | Medical News and Health Inf...
154. Medicin'es Next Big Thing? Catching Cancer With Ma...
155. Closing the Quality Gap: Revisiting the State of t...
156. Scientists prove new technology to control malaria...
157. CDC Data & Statistics | Feature: Colorectal (Colon...
158. CDC Data & Statistics | Feature: Insufficient Slee...
159. Information for Healthcare Professionals (Drugs) >...
160. Birth Even a Few Weeks Early May Raise Odds for AD...
161. Minority Kids With Heart Defects More Likely to Di...
162. Gallbladder risk no higher with newer "Pill": Medl...
163. Women Taking Calcium Supplements May Risk Heart He...
164. Barriers in Identification and Referral to Genetic...
165. Economic impact of a genetic test for cisplatin-in...
166. EMAS position statement: Managing menopausal women...
167. A Population-Based Survey in Australia of Men's an...
168. The influence of family history and histological s...
169. KRAS Mutations in Ovarian Cancer -- Maybe Not
170. Drug Safety Information for Healthcare Professiona...
171. Depression After Brain Injury: A Guide for Patient...
172. NIAMS Researchers Explain Why Combined Osteoporosi...
173. Genes May Affect Whether People Heed Advice: Medli...
174. Viral Hepatitis: New Posters Available
175. Assessing Completeness of Perinatal Hepatitis B Vi...
176. Registration Still Open || Chronic Viral Hepatitis...
177. Recent Advances in the Diagnosis and Treatment of ...
178. Recent Advances in the Diagnosis and Treatment of ...
179. Pesticide Exposure in Pregnancy Linked to Lower IQ...
180. Corticosteroid Creams Safe for Kids With Eczema: S...
181. Gut Bacteria Falls Into Three Major Types: Medline...
182. Student Bullying Linked to Family Violence: CDC: M...
183. Behavioral Therapy May Reduce Tourette Tics, Sympt...
184. No evidence coffee ups risk of high blood pressure...
185. ACE Inhibitors Seem to Raise Risk of Breast Cancer...
186. Study uncovers genes that aid malarial resistance:...
187. Higher Death Rates Seen in Central Line Dialysis P...
188. Chronic Kidney Disease Tied to Heart Problems in E...
189. Newer 'Pill' Linked to Higher Risk of Blood Clots:...
190. Research Activities, April 2011: Chronic Disease: ...
191. Neuroprotection Exploratory Trials in Parkinson's ...
192. Common genetic variant linked to pulmonary fibrosi...
193. Research Activities, April 2011: Chronic Disease: ...
194. Many kids with diabetes have other immune diseases...
195. Press Announcements > FDA approves the first vacci...
196. Safety Alerts for Human Medical Products > Tysabri...
197. Minority Women's Health - Asian-Americans - Heart ...
198. American Society of Clinical Oncology Clinical Pra...
199. National Guideline Clearinghouse | Recommended imm...
200. National Guideline Clearinghouse | The natural his...
201. National Guideline Clearinghouse | Techniques for ...
202. National Guideline Clearinghouse | Techniques for ...
203. National Guideline Clearinghouse | Radiographic as...
204. National Guideline Clearinghouse | Preoperative pa...
205. National Guideline Clearinghouse | Management of a...
206. National Guideline Clearinghouse | Laminectomy and...
207. National Guideline Clearinghouse | Indications for...
208. National Guideline Clearinghouse | Functional outc...
209. National Guideline Clearinghouse | Electrophysiolo...
210. National Guideline Clearinghouse | Clinical progno...
211. National Guideline Clearinghouse | Cervical surgic...
212. National Guideline Clearinghouse | Cervical lamino...
213. National Guideline Clearinghouse | Cervical lamino...
214. National Guideline Clearinghouse | Cervical lamine...
215. National Guideline Clearinghouse | Anterior cervic...
216. Dietary, lifestyle changes can significantly reduc...
217. Stroke survival among seniors better in sociable n...
218. NIH-supported survey to study functional change in...
219. National Comprehensive Cancer Network | Our Progra...
220. Scientific community leaders meet May 2 to begin a...
221. NIH statement on World Malaria Day, April 25, 2011...
222. NCCN 2011 Nursing Program Webinars
223. NCCN 2011 Congress Series: Breast Cancer
224. NCCN Oncology Case Management Program
225. JAMA, the Journal of the American Medical Associat...
226. A Predictive Model for Progression of Chronic Kidn...
227. Detection of Chronic Kidney Disease With Creatinin...
228. Whole-Genome Sequencing, April 20, 2011, Pasche an...
229. Use of Whole-Genome Sequencing to Diagnose a Crypt...
230. Identification of a Novel TP53 Cancer Susceptibili...
231. PLoS ONE: Activation of p53 by Nutlin-3a Induces A...
232. Targeted Genomic Disruption of H-Ras Induces Hypot...
233. Risk of triple-class virological failure in childr...
234. Obesity - Stroke Connection
235. Breast Implants, Lymphoma Link Seen: MedlinePlus
236. Children With HIV at Higher Risk of Drug Resistanc...
237. Generation Alzheimer's - The Defining Disease Of T...
238. “Stupid Cancer Show” to Host Program on Clinical T...
239. Two-Year Project Launched to Standardize Cytogenet...
240. Breast Cancer Guidelines Proposed for Low- and Mid...
241. NCI Cancer Classroom Webinar Series Kicks Off Apri...
242. NCI Recovery Act Web Site Highlights Small Busines...
243. 1. New Treatment for Medullary Thyroid Cancer || 2...
244. Cediranib to Treat Alveolar Soft Part Sarcoma || N...
245. Debunking Cancer Myths, One Phone Call at a Time |...
246. Investigating Nature's Mysteries for Drug Developm...
247. Inside NCI: A Conversation with Dr. Lauren Wood ||...
248. Signaling Molecule Selectively Kills Breast Cancer...
249. Genetic Study Yields New Clues to Melanoma || NCI ...
250. Cancer Burden among People Infected with HIV Chang...
251. Active Surveillance May Be Preferred Option in Som...
252. Press Announcements > FDA approves Rituxan to trea...
253. Alzheimer's diagnostic guidelines updated for firs...
254. LEISHMANIASIS, VISCERAL, CASOS HUMANOS- ARGENTINA ...
255. KPC, INTRAHOSPITALARIA, AUMENTO DE CASOS - ARGENTI...
256. NIMH · Mice with Autism-related Mutations Replicat...
257. Off-Label Use of Clotting Drug Soars, Report Finds...
258. Building Resilience in Children and Youth Dealing ...
259. NIMH · Statistics · Any Anxiety Disorder Among Chi...
260. Chronic fatigue rare but serious in teens: Medline...
261. Can Common Virus, Lack of Sunlight Boost MS Risk?:...
262. NIMH · Statistics · Major Depressive Disorder in C...
263. CDC - VRE in Healthcare Settings - HAI
264. CDC - 2011 Estimates of Foodborne Illness
265. Fewer U.S. women dying of lung cancer -study
266. Half of men may have HPV infections: study
267. Health risks fade after estrogen therapy stops: st...
268. Fewer Than Half of Ovarian Cancer Patients Get Car...
269. Pleomorphic Lobular Carcinoma in Situ: A Divergent...
270. NCCN CML Guidelines Now Include Second- and Third-...
271. NCCN Issues Its First Clinical Guideline for Post-...
272. Information by Drug Class > Opioid Drugs and Risk ...
273. Adults represent a majority of inhalant treatment ...
274. Adverse Events Reporting System (AERS) > The Adver...
275. Drug Safety and Availability > Medication Guides
276. Biosimilars: More Education Is Needed
277. Sodium Reduction: Time for Choice | CDC's Public H...
278. NIDA raises the curtain on addiction, April 18, 20...
279. NEI names 2011 Healthy Vision Community Awards rec...
280. New Treatment for Urinary Tract Infections Called ...
281. MYH9-related disorder - Genetics Home Reference
282. Surprising Molecule Tied to Rare Disease - NIH Res...
283. Blood DNA Test Detects Heart Transplant Rejection ...
284. A Genomic Survey of Melanoma - NIH Research Matter...
285. FDA orders safety studies for some asthma drugs: M...
286. High bacteria levels in meat at U.S. stores: repor...
287. Problem Drinking May Make Hospital Infections More...
288. Alcohol-Energy Drink Combo Riskier Than Booze Alon...
289. HeartWare device had 9.2 percent thrombosis rate i...
290. Alcoholic Parents May Predispose Kids to Drinking ...
291. Do Immune System Ills Help Drive Type 2 Diabetes?:...
292. Having Both Autism and Epilepsy Linked to Raised D...
293. Estrogen's Role in Breast Cancer Can Fluctuate: Me...
294. Foodborne Illness in the United States || CDC Data...
295. Differential microRNA regulation of HLA-C expressi...
296. High-resolution characterization of a hepatocellul...
297. Genome-wide association study identifies a suscept...
298. National, regional, and worldwide estimates of sti...
299. Modelling schizophrenia using human induced plurip...
300. Rotator Repair -- Research Summary | Medical News ...
301. New Knee = A Leg Up For Patients -- In Depth Docto...
302. Doubling Prostate Cancer Survival -- Research Summ...
303. Drano For Clogged Arteries -- In Depth Doctor's In...
304. KPC, CASOS CONFIRMADOS, UTI - URUGUAY
305. DENGUE, EPIDEMIA EXTENSA: ACTUALIZACIÓN - PARAGUAY...
306. Antimicrobial Resistance Across the Continuum of C...
307. Hospital Acquired Infections (HAI) Prevention Rese...
308. Make Every Injection Safe!
309. CDC Commentary: Preventing Carbapenem-Resistant En...
310. Prevention of Device-Related Infections: A Global ...
311. Preventing Transmission of Infectious Agents in He...
312. Preventing Bloodstream Infection During Hemodialys...
313. Medication Use in Pregnancy
314. What's New in Blood Testing for TB Infection?
315. Neglected Infections of Poverty - Toxocariasis
316. Putting a Stop to MRSA: Active Detection and Isola...
317. CDC - National Center for Health Statistics Homepa...
318. Sodium Reduction: Time for Choice >> CDC's Grand R...
319. AHRQ Innovations Exchange
320. Staying Healthy Through Education and Prevention (...
321. Maternal-Fetal Surgical Procedures - Technical Bri...
322. Therapies for Children With Autism Spectrum Disord...
323. Use of Recombinant Human Growth Hormone for Pediat...
324. Screening: Testicular Cancer
325. Epidemiology and Prevention of Vaccine-Preventable...
326. NIH scientists identify gene that could hold the k...
327. NIH researchers complete whole-exome sequencing of...
328. tocilizumab | Press Announcements > FDA approves A...
329. Genetic Testing and Parkinson Disease: Assessment ...
330. Predictors of contralateral breast cancer in BRCA1...
331. Evaluation of physician knowledge and referral pra...
332. ASCO, NCCN Recommend EGFR Testing in Advanced Lung...
333. Suicide Rates Rise and Fall With the Economy: CDC:...
334. Nervous System Imbalance May Cause Fatigue in Brea...
335. FDA finds more blood cancer with TNF blocker drugs...
336. Kidney Transplant Patients at Risk of Narrowed Art...
337. Latest Artificial Pancreas Trials Reduce Risk of L...
338. Depression After Brain Injury: A Guide for Patient...
339. Drug Safety and Availability > FDA Drug Safety Com...
340. Drug Safety and Availability > FDA Drug Safety Com...
341. Childhood Trauma's Impact on Health Risks | Awaren...
342. Thyroid Regulates More Than Just Hormones | Medica...
343. Treating Clients With Traumatic Brain Injury | SAM...
344. Talking with Your Adult Patients about Alcohol, Dr...
345. Emerging Infectious Diseases Journal Homepage | CD...
346. Male Victims of 'Intimate Terrorism' Can Experienc...
347. Brain May Shrink in Decade Before Alzheimer's Symp...
348. New RX for Large Brain Aneurysm: MedlinePlus
349. Studies Highlight Challenge of Controlling Resista...
350. Donor Lungs Kept Alive Outside Body: MedlinePlus
351. Genetic defect suggests high blood pressure may co...
352. Sudden cardiac death affects about 1 in 44,000 NCA...
353. Death rates after hospitalization down for oldest ...
354. Get With The Guidelines hospitals deliver equitabl...
355. Virtual reality may lead to real-world improvement...
356. Blood pressure’s internally-driven daily rhythm un...
357. Diesel-engine exhaust filter reduces harmful parti...
358. Announcement: Call for Papers: Journal Issue on In...
359. Human Rabies --- Michigan, 2009
360. Tracking Progress Toward Global Polio Eradication ...
361. APPENDIX B | Biosafety Laboratory Competency Guide...
362. APPENDIX A | Guidelines for Biosafety Laboratory C...
363. Guidelines for Biosafety Laboratory Competency
364. Limb-girdle muscular dystrophy - Genetics Home Ref...
365. Drug Safety and Availability > FDA Drug Safety Com...
366. INFLAMMATORY BOWEL DISEASE | Organization of Terat...
367. PSORIASIS/PSORIATIC ARTHRITIS | Organization of Te...
368. Seroprevalence of Herpes Simplex Virus Type 2 Amon...
369. Fertility preservation in women with early stage c...
370. Complementary and alternative medicine dialogue la...
371. Products - Data Briefs - Number 61 - April 2011
372. 25 Important Global Health Facts Every American Ne...
373. CDC - Blogs - Safe Healthcare – Preventing MRSA in...
374. CDC - Blogs - Safe Healthcare – Preventing MRSA in...
375. CDC - Blogs - Safe Healthcare – Preventing MRSA in...
376. Press Announcements > FDA approves new treatment f...
377. Photochemical & Photobiological Sciences | Home-A ...
378. 2012 National STD Prevention Conference
379. Recently Updated Advisory Committee Materials
380. NIH Fact Sheets - Uterine Fibroids
381. The Long Road to Discovery [NIDCD]
382. Male Victims of Domestic Abuse May Show Signs of P...
383. Vitamin D may not explain fractures in babies: Med...
384. An Apple a Day May Help Keep Heart Disease Away: M...
385. Clues to Why Rheumatoid Arthritis Drug Humira Fail...
386. Extended HPV Vaccine Schedule Seems Effective: Med...
387. Genital Herpes Can Be Spread When Lesions Aren't P...
388. Scarring of Transplanted Kidneys Less of a Problem...
389. Clinical Alert: Angioplasty Combined with Stenting...
390. U.S. Reports Drop in AIDS-Related Cancers: Medline...
391. Roche's diet drug tied to kidney damage: MedlinePl...
392. The kidney spiral: High Blood Pressure and Kidney ...
393. Omega-3s for Postpartum Depression? | Medical News...
394. Stopping Involuntary Movements | Medical News and ...
395. New Way to Treat TB | Medical News and Health Info...
396. More Flexible HPV Vaccines | Medical News and Heal...
397. Insulin: Predictor for Alzheimer's? | Medical News...
398. Preventing Chronic Disease: May 2011: Table of Con...
399. Preventing Chronic Disease: May 2011: 10_0036 | Id...
400. e- Boletín DROGAS Y MEDICAMENTOS | Año Nº II - Nº ...
401. National Guideline Clearinghouse | Recurrent urina...
402. National Guideline Clearinghouse | Guidelines for ...
403. National Guideline Clearinghouse | Antibiotic prop...
404. CDC Data & Statistics | Feature: Cancer Rates Cont...
405. Drug Safety and Availability > FDA Drug Safety Com...
406. Steroid medications not tied to oral birth defects...
407. Sleep Problems May Linger After Childhood Cancer: ...
408. New Tests Could Spot Which Kidney Patients Will Do...
409. Obese Kids' Wrist Size May Predict Heart Disease: ...
410. Drug Memantine Ineffective for Mild Alzheimer's, S...
411. Acne Antibiotics Not Linked to Drug Resistance: Me...
412. March 2011 Safety Labeling Changes: 55 Medical Pro...
413. Results of Brain Imaging May Help Explain Why More...
414. Drug Approvals and Databases > Bioresearch Monitor...
415. Oxford Journals | Medicine | JNCI J Natl Cancer In...
416. Distribution of cancers in the HIV/AIDS population...
417. NIH researchers identify cause and new treatment f...
418. National Guideline Clearinghouse | Management of d...
419. National Guideline Clearinghouse | Management of a...
420. National Guideline Clearinghouse | Management of a...
421. National Guideline Clearinghouse | Management of a...
422. National Guideline Clearinghouse | General princip...
423. National Guideline Clearinghouse | Diagnosis and m...
424. National Guideline Clearinghouse | Primary open-an...
425. National Guideline Clearinghouse | Primary open-an...
426. National Guideline Clearinghouse | Primary angle c...
427. Preventing Pressure Ulcers in Hospitals: A Toolkit...
428. Mapping Recombination Hotspots - NIH Research Matt...
429. More Young Neurons Equals Better Brain Function - ...
430. New Genetic Risk Factors for Alzheimer's Disease -...
431. National Guideline Clearinghouse | AHRQ Evidence R...
432. ICSI - Guidelines
433. National Guideline Clearinghouse | Trabectedin for...
434. National Guideline Clearinghouse | Certolizumab pe...
435. National Guideline Clearinghouse | Capecitabine fo...
436. National Guideline Clearinghouse | Adalimumab, eta...
437. Limb-girdle muscular dystrophy - Genetics Home Ref...
438. Acute promyelocytic leukemia - Genetics Home Refer...
439. CARASIL - Genetics Home Reference | Cerebral autos...
440. Parkinson's May Have Links to Certain Cancers, Stu...
441. Hormone Linked to Absence of Periods in Women With...
442. Unemployment Plays Role in Early Deaths, Research ...
443. Spinal Fusion for Scoliosis Seems Effective Years ...
444. Scientists find way to map brain's complexity: Med...
445. Bypass surgery, medications both options to be con...
446. AChemS 2011 – annual meeting of chemosensory resea...
447. New warm line helps clinicians tackle patients' su...
448. Meals & Multitasking: Bad Combo -- Research Summar...
449. The Rise of a Cancer -- Research Summary | Medical...
450. Chemo Blast For Melanoma -- Research Summary | Med...
451. Curing Diabetes -- Research Summary | Medical News...
452. Fat Grafting For Faces -- Research Summary | Medic...
453. NCIRD: Instant Childhood Immunization Scheduler
454. CDC - Annual Reports - Antimicrobial Resistance
455. CDC - Blogs - Safe Healthcare – SHEA Scientific Me...
456. CDC - Blogs - Safe Healthcare – World Health Day 2...
457. CDC - ADDM, Autism Spectrum Disorders - NCBDDD
458. RFA-AI-11-013: Allergen Epitope Research and Valid...
459. Vaccines: Adult Immunization Scheduler
460. Health technology assessment in the era of persona...
461. Genetic susceptibility and the setting of occupati...
462. PHG Foundation | Improving diagnosis and care for ...
463. Interest in Genetic Testing for Modest Changes in ...
464. Genome Biology | Full text | A standard variation ...
465. Global analysis of disease-related DNA sequence va...
466. New Study Reveals 1 Million Human Genome Sequence ...
467. Global analysis of disease-related DNA sequence va...
468. Polygenic susceptibility to prostate and breast ca...
469. Association Between BRCA2 Mutations And Improved S...
470. Family Health History Study Takes FLIGHT at BWH- B...
471. A family history intervention. [AAOHN J. 2011] - P...
472. Sudden Cardiac Death More Common in Young Athletes...
473. Do At-Home Genetic Tests Tell Too Much and Explain...
474. BabysFirstTest: The Newborn Screening Clearinghous...
475. Significant differences among physician specialtie...
476. Pharmacogenomic testing: Relevance in medical prac...
477. Cystic Fibrosis Carrier Screening in Obstetric Cli...
478. VRC Vaccine Research Studies Profiles
479. NIAID Seeks Volunteers for Clinical Studies on New...
480. NCTR Publications > NCTR Research Highlights
481. Current Issue of Thrombosis and Haemostasis
482. Associations of Self-Reported Periodontal Disease ...
483. ACIP Provisional Recommendations for Health Care P...
484. Safety Alerts for Human Medical Products > Revlimi...
485. Vaccinia Virus Infections, Maryland, USA | CDC EID...
486. Press Announcements > FDA approves Horizant to tre...
487. Long-Term Ecstasy Users at Risk for Brain Damage, ...
488. Stent studies don't reflect "real world" patients:...
489. Risks of Estrogen Hormone Therapy Seen to Fade Aft...
490. High Blood Pressure May Come From Mom | Medical Ne...
491. HPV and Lung Cancer Linked? | Medical News and Hea...
492. New Target Drug For Lung Cancer? | Medical News an...
493. Breast Milk: Key to Predicting Cancer? | Medical N...
494. Safety Alerts for Human Medical Products > Yervoy ...
495. CDC Data & Statistics | Feature: Countries of Orig...
496. Using a Comprehensive Unit-based Safety Program to...
497. Effects of a restricted elimination diet on the be...
498. The Lancet: Selected articles from 2011
499. Blood Products Advisory Committee > 2011 Meeting M...
500. Teen Weight Affects Later Heart Disease Risk: Stud...
501. Years Later, Victims of Critical Respiratory Illne...
502. Device Approved to Treat Brain Aneurysm: MedlinePl...
503. Study Probes Potential Link Between Welding, Parki...
504. Progesterone reduces rate of early preterm birth i...
505. NIMH · Depressed Teens with History of Abuse Less ...
506. chronic fatigue syndrome (CFS) | Press Announcemen...
507. Amount of HIV in Genital Fluid Linked to Transmiss...
508. Coffee Addiction May Be Grounded in Genes: Medline...
509. Effect of Antidepressants on the Course of Disabil...
510. Nutrient Intakes and Patterns: European Prospectiv...
511. Alcohol attributable burden of incidence of cancer...
512. National Guideline Clearinghouse | Perioperative p...
513. National Guideline Clearinghouse | Diagnosis and t...
514. National Guideline Clearinghouse | Stroke recognit...
515. National Guideline Clearinghouse | Secondary preve...
516. National Guideline Clearinghouse | Rehabilitation....
517. National Guideline Clearinghouse | Organisation of...
518. National Guideline Clearinghouse | Managing compli...
519. National Guideline Clearinghouse | Early assessmen...
520. National Guideline Clearinghouse | Community parti...
521. National Guideline Clearinghouse | Acute medical a...
522. Surveillance for Laboratory-Confirmed Sporadic Cas...
523. Notes from the Field: Measles Outbreak --- Hennepi...
524. Vital Signs: Teen Pregnancy --- United States, 199...
525. Assessing Completeness of Perinatal Hepatitis B Vi...
526. Assessment of ESSENCE Performance for Influenza-Li...
527. Outbreak of Invasive Listeriosis Associated with t...
528. Measles Imported by Returning U.S. Travelers Aged ...
529. Vandetanib | About the Center for Drug Evaluation ...
530. Drug Safety and Availability > FDA Drug Safety Com...
531. WHO | World Health Day 2011
532. Patients on Higher Doses of Prescription Painkille...
533. Study questions heartburn drugs for kids: MedlineP...
534. MRI finds earlier breast cancers in gene carriers:...
535. Two Different Heart Drugs May Work Equally Well fo...
536. Long-term care is newest topic on NIHSeniorHealth ...
537. NIH, USU study maps hotspots of genetic rearrangem...
538. Analysis of opioid prescription practices finds ar...
539. Free Telephone Workshop Series for Cancer Survivor...
540. Member Sites Selected for Cancer Immunotherapy Tri...
541. NIH Research Plan Aims to Prevent and Treat Obesit...
542. CMS Issues Proposed Decision Memo on Medicare Cove...
543. FDA Approves New Treatment for Late-Stage Melanoma...
544. NCI Cancer Bulletin for April 5, 2011 - National C...
545. Importance of Tissue Samples - TCGA
546. Genome Study of Multiple Myeloma Opens New Avenues...
547. For People with Rare Skin Cancer Syndrome, Drug Br...
548. Menopausal Estrogen Therapy Benefits and Risks Var...
549. Test May Detect Mesothelioma at the Earliest Stage...
550. Combination of Two Targeted Cancer Drugs Appears S...
551. Breast Cancer Genomes Sequenced to Study Drug Resp...
552. Immunotherapy Targets Pancreatic Tumors from the O...
553. Risk of Second Cancer Following Radiation Therapy ...
554. Patients Taking Imatinib for CML Have Similar Risk...
555. Latest Surveillance Data Show Cancer Cases and Dea...
556. Crossing Disciplines to Explore Questions about Ca...
557. Clamp Device for Leaky Heart Valve Seems Effective...
558. Blood Test Holds Hope for Spotting Lung Cancer in ...
559. Ovarian Cancer Prognosis May Depend on Gene Mutati...
560. Brains of People with Autism Focus More on Visual ...
561. Evidence Weak to Support Many Medications for Auti...
562. HPV Might Be Linked to Lung Cancer: MedlinePlus
563. Monthly Aspirin Use Linked to Lower Pancreatic Can...
564. Compulsive Eaters May Have 'Food Addiction,' Study...
565. Too Many Hours at Work Might Harm the Heart: Medli...
566. Cases of 'Flattened Head' Babies on the Rise, Stud...
567. National Guideline Clearinghouse | Guidelines by T...
568. National Guideline Clearinghouse | Guidelines by T...
569. National Guideline Clearinghouse | Screening of th...
570. National Guideline Clearinghouse | Screening of si...
571. National Guideline Clearinghouse | Management of v...
572. National Guideline Clearinghouse | Management of i...
573. National Guideline Clearinghouse | Management of c...
574. National Guideline Clearinghouse | HIV/AIDS eviden...
575. National Guideline Clearinghouse | Guideline Synth...
576. National Guideline Clearinghouse | Febrile seizure...
577. Screening: Testicular Cancer
578. CDC and ASTHO Release Policy Toolkit for Healthcar...
579. Vaccines: Vac-Gen/Shortages/main page
580. Recently Updated Advisory Committee Materials
581. Postmarket Drug Safety Information for Patients an...
582. Treatments Show Promise in Reducing Autism-related...
583. NIH launches training institute on dissemination a...
584. NIH study finds genetic clues to major cause of ki...
585. NIH and CDC update guidelines to protect patients ...
586. Nurturing newborn neurons sharpens minds in mice, ...
587. Studies find possible new genetic risk factors for...
588. Vaccines and Related Biological Products Advisory ...
589. Genetic Variations Affect Control of the Genome
590. Eye Development Error Causes Cataracts, Glaucoma
591. Breaking Down Pancreatic Tumor Defenses
592. Does Stress Reduction Benefit Cancer Patients' Hea...
593. Research Warns of Overuse of Powerful Class of Ant...
594. Minimally Invasive Heart-Valve Procedure Shows Pro...
595. Heart Attack Risk Plagues Post-Katrina New Orleans...
596. Add Cancer to Health Risks of Diabetes: Study: Med...
597. Study Links Smoking, Breast Cancer in Older Women:...
598. Most Breast Tumors Have Unique Genetic 'Fingerprin...
599. Scientists find five new Alzheimer's risk genes: M...
600. Vibrio cholerae in Traveler from Haiti to Canada |...
601. CDC and NIH Update Guidelines to Protect Patients ...
602. CDC - Blogs - Safe Healthcare – New guidelines to ...
603. American Journal of Infection Control - Home
604. Oxford Journals | Medicine | Journal of Infectious...
605. Oxford Journals | Medicine | Clinical Infectious D...
606. Guidelines for the Prevention of Intravascular Cat...
607. Management of Acute Otitis Media: Update: Structur...
608. Health Literacy Interventions and Outcomes, Update...
609. Lactose Intolerance and Health: Structured Abstrac...
610. National Guideline Clearinghouse | Guidelines by T...
611. Emerging Infectious Diseases Journal Homepage | CD...
612. Drug-Resistant Pandemic (H1N1) 2009, South Korea |...
613. Recent Clonal Origin of Cholera in Haiti | CDC EID...
614. Molecular Discrimination of Sheep BSE | CDC EID
615. Rapid Genotyping of Swine Influenza Viruses | CDC ...
616. Bacterial Meningitis and Hib Vaccine, Malawi | CDC...
617. Parapoxvirus Infections of Red Deer | CDC EID
618. Management by Primary Care Clinicians of Patients ...
619. Using the AHRQ Medical Office Survey on Patient Sa...
620. EU Cross Border Health Care Directive | www.eurord...
621. What can sociology teach us about the rare disease...
622. The new EU Directive on Cross-Border Health Care i...
623. Acute Cytomegalovirus Pneumonitis in Patient with ...
624. Livestock-associated Staphylococcus aureus in Chil...
625. Sequence Analysis of Feline Coronaviruses and the ...
626. Effects of Vaccination against Pandemic (H1N1) 200...
627. Pandemic (H1N1) 2009 Virus in 3 Wildlife Species, ...
628. Hemagglutinin 222 Variants in Pandemic (H1N1) 2009...
629. School Closure from Pandemic (H1N1) 2009 | CDC EID...
630. Imported Rabies, European Union and Switzerland, 2...
631. Cytomegalovirus Viremia, Pneumonitis, and Tocilizu...
632. CDC | What's New | Emergency Preparedness & Respon...
633. Concurrent Influenza and Shigellosis Outbreaks, Pa...
634. Smoking Early in Pregnancy Raises Risk of Heart De...
635. For Young Kids With Pneumonia, Timing of Antibioti...
636. Early Brain Therapy May Help Movement in Dystonia ...
637. Public Health Focus > Radiation Safety
638. American Association for the Study of Liver Diseas...
639. NIH investigators find link between DNA damage and...
640. Some Type 1 Diabetics Seem Shielded Against Compli...
641. 50-year mortality trends in children and young peo...
642. FDA Hepatitis Update - Labeling changes to Tyzeka ...
643. A New Era of Hepatitis C Therapy Begins — NEJM
644. Current priorities for public health practice in a...
645. European Journal of Human Genetics - Strengthening...
646. PLoS Medicine: Strengthening the Reporting of Gene...
647. Genomics|HuGENet|Workshops|Agenda|December 16, 200...
648. Severe reaction to epilepsy drug linked to genetic...
649. IL28B single nucleotide polymorphisms in the treat...
650. PHG Foundation | Genetic defects in immune system ...
651. Boceprevir for Untreated Chronic HCV Genotype 1 In...
652. Carbamazepine-induced toxic effects and HLA-B*1502...
653. PLoS Medicine: Mutations in Complement Regulatory ...
654. External Quality Assessment for KRAS Testing Is Ne...
655. Diagnosis and management of glutaric aciduria type...
656. Perceived Utility of Parent-Generated Family Healt...
657. Attitudes Toward Direct-to-Consumer Advertisements...
658. ACOG Updates Cystic Fibrosis Screening Guidelines
659. New guidelines highlight genetic testing use in he...
660. Guidances (Drugs) > Individual Product Bioequivale...
661. Guidance for Industry Postmarketing Studies and Cl...
662. Gastric Banding Problems | Medical News and Health...
663. HHS Panel Updates Guidelines for the Use of Antire...
664. Effect of Transmitted Drug Resistance on Virologic...
665. BARDA funds advanced development of new influenza …

►  marzo (707)
►  febrero (615)
►  enero (649)

►  2010 (6309)
►  diciembre (640)
►  noviembre (596)
►  octubre (608)
►  septiembre (561)
►  agosto (468)
►  julio (489)
►  junio (463)
►  mayo (615)
►  abril (504)
►  marzo (510)
►  febrero (345)
►  enero (510)

►  2009 (4504

Fatal Human Case of WEE | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011
Letter
Fatal Human Case of Western Equine Encephalitis, Uruguay
Adriana Delfraro, Analía Burgueño, Noelia Morel, Gabriel González, Alicia García, Juan Morelli, Walter Pérez, Héctor Chiparelli, and Juan Arbiza
Author affiliations: Universidad de la República, Montevideo, Uruguay (A. Delfraro, A. Burgueño, J. Arbiza); Ministerio de Salud Pública, Montevideo (N. Morel, H. Chiparelli); and Hospital Británico, Montevideo (G. González, A. Garcia, J. Morelli, W. Pérez)


Suggested citation for this article

To the Editor: The genus Alphavirus (family Togaviridae) comprises 29 viral species (1), grouped in at least 7 antigenic complexes by their serologic cross-reactivity (2). They are maintained in nature through enzootic cycles involving arthropods as vectors with subsequent amplification in small mammals or birds, and epizootic cycles between mosquitoes and large mammals such as horses or humans.

Few reports have been made of the circulation of alphaviruses in Uruguay. A serologic study conducted in 1970 found antibodies to western (WEEV) and eastern equine encephalitis viruses by using complement fixation and hemagglutination inhibition tests in serum specimens from children (3). In 1972–1973, epizootics in horses caused by WEEV were reported in Argentina and Uruguay, and WEEV was isolated from a sick horse (4).

We report a fatal case of viral encephalitis in April 2009 in Montevideo, Uruguay, in a previously healthy 14-year-old boy. Four days before he sought treatment, he had fever, asthenia, and headaches. At hospital admission (April 12, 2009), he was febrile and without neurologic signs; amoxicillin treatment was initiated. Results of a computed tomography scan of the brain were normal.

On day 1, headache, vomiting, neck stiffness, and partial left seizures on the left side developed. Also exhibited were consciousness depression (Glasgow Coma Scale 12 points), hyperreflexia, and bilateral Babinski sign. A cerebrospinal fluid (CSF) sample was negative for bacteria in cultures. An electroencephalogram showed diffuse brain suffering. The patient was brought to the intensive care unit with a clinical diagnosis of viral encephalitis. Over the next 24–36 hours, intracranial hypertension developed, and medical treatment was given (sedation, hyperventilation, mannitol, and barbiturates). Conscience depression progressed to a deeper level, and a computed tomography scan of the brain showed dilatation of the temporal ventricles and compression of the peritroncal and sylvian cisterns. During the next 48 hours, the coma level went deeper, reaching 6 on the Glasgow Scale. Another CSF specimen was taken, and PCR results were negative for herpesvirus and enterovirus. Glasgow Coma Scale level was 3 on April 15, and a decompressive craniectomy was done. Seventy-two hours after admission, the patient died.

The patient's plasma and CSF were tested for antibodies to dengue and West Nile viruses (immunoglobulins M and G) through ELISA (Focus Technologies, Cypress, CA, USA) and for St. Louis encephalitis and dengue virus by M antibody-capture–ELISA (5). RNA was extracted from plasma and CSF, followed by a generic nested reverse transcription–PCR (RT-PCR) for flaviviruses (6). Serologic and molecular test results were negative for the above-mentioned pathogens. Then we performed a generic nested RT-PCR (7), which amplifies 448 bp at first round and 195 bp (second round) of the alphavirus NSP4 gene. Also, a heminested PCR was done (products 372 bp and 303 bp); RNA from Venezuelan equine encephalitis virus Tc-83 (provided by M. Contigiani, Universidad de Córdoba) was used as positive control. The target region is informative enough to allow the precise identification of the most relevant alphaviruses by sequencing and phylogenetic analysis. Alphavirus genome amplification was achieved for the CSF specimen collected at admission to the hospital. Plasma and a second CSF specimen were PCR negative. To confirm these findings, another nested RT-PCR reaction targeting the NSP1 gene was done as described previously (8). A 208-bp amplicon, which corresponded to the expected size for WEEV, was obtained from plasma and the first CSF specimen.

Figure

Figure. A) Phylogenetic tree obtained by maximum likelihood analysis of sequences corresponding to the alphavirus NSP4 gene...


Sequence analyses were conducted on the NSP4 fragments. Maximum likelihood (9) and Bayesian (10) phylogenetic analyses gave similar results. The Figure, panel A, shows that sample LCR/09-303 is part of a well-supported clade (aLRT = 0.99), which groups WEEVs. The sequence LCR/09-303 is a sister taxon to sequences GQ287641 and GQ287642, with poor support (Figure, panel B) (Appendix Table). These are reference WEEV USA strains (Imperial and Kern) obtained from Culex tarsalis mosquitoes. Our sample and the mentioned sequences are part of a well-supported clade (aLRT = 0.85), together with GQ287645, AF214040, and FJ786260. These are also USA strains; 2 were isolated from infected horses and 1 from Cx. tarsalis mosquitoes. Notably, our sequence is distantly related to GQ287646, which was isolated from Culex spp. mosquitoes in Chaco, Argentina. The nucleotide sequence of the positive control VEEV-Tc83 is correctly placed in the VEEV clade.

Clinical and laboratory findings showed that the illness described here was compatible with viral encephalitis. Using a generic RT-PCR assay on an early CSF sample, we amplified a partial sequence (NSP4 gene) of an alphavirus. Phylogenetic analyses showed that the patient's sequence grouped with sequences from WEEV, with high statistical support. A second RT-PCR assay on the NSP1 gene enabled us to obtain an amplification of 208 bp, which is consistent with the expected size for WEEV. Therefore, we concluded that the fatal disease was likely caused by WEEV. Since the 1970s, to our knowledge, the presence of WEEV (or other alphaviruses) in Uruguay has not been documented. Moreover, no recent reports have been made of genome detection of WEEV in encephalitis cases in the region.

Although the case described here may be rare, the etiology of many viral encephalitides in Uruguay remains unknown. Serologic studies in horses and studies to detect arboviruses in mosquito populations are being conducted to investigate the status of arbovirus infections in Uruguay.

Acknowledgments
We thank José C. Russi for his invaluable scientific advice during all the stages of this work and Gabriela Algorta for her help and interest in our research.

full-text:
Fatal Human Case of WEE | CDC EID


Suggested Citation for this Article
Delfraro A, Burgueño A, Morel N, González G, García A, Morelli J, et al. Fatal human case of Western equine encephalitis, Uruguay [letter]. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://www.cdc.gov/EID/content/17/5/952.htm


DOI: 10.3201/eid1705.101068


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Adriana Delfraro, Sección Virologia, Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo, Uruguay; email: adriana@fcien.edu.uy

Widespread Availability of Artemisinin Monotherapy in the United States | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011
Letter
Widespread Availability of Artemisinin Monotherapy in the United States
Robert M. Rakita and Uma Malhotra
Author affiliations: University of Washington, Seattle, Washington, USA (R.M. Rakita); and Virginia Mason Medical Center, Seattle (U. Malhotra)


Suggested citation for this article

To the Editor: Artemisinin-based combination therapies are recommended as first line treatments for Plasmodium falciparum malaria in most areas of the world. The article by Shahinas et al. (1) describes a patient who had P. falciparum malaria after returning from Nigeria. Her isolate had an elevated 50% inhibitory concentration to artemisinin derivatives. She had obtained artesunate in Nigeria and took it weekly for malaria prophylaxis, which might have contributed to the relative resistance found.

Figure

Figure. Bottle of artemisinin, available over-the-counter as an herbal supplement.


In 2009, one artemisinin-based combination therapy (artemether/lumefantrine) became available for use in the United States. However, it is not widely appreciated that artemisinin is actually available in the United States as an herbal supplement for over-the-counter purchase (2). It is marketed for general health maintenance and for treatment of parasitic infections and cancers (Figure), although as with other supplements it is not intended to diagnose, treat, cure, or prevent any disease. As in the patient described by Shahinas et al., widespread use of artemisinin or its derivatives as monotherapies could potentially lead to progressively increasing resistance in P. falciparum malaria (3). Studies in western Cambodia, where artemisinin monotherapy has been available for many years, have revealed in vivo artesunate resistance, with markedly decreased parasite clearance times (3). Progressive spread of artemisinin resistance could have disastrous consequences for the global control of malaria. Thus, minimally regulated use of potent compounds in dietary supplements has the potential for major public health implications.

References
1.Shahinas D, Lau R, Khairnar K, Hancock D, Pillai DR. Artesunate misuse and Plasmodium falciparum malaria in traveler returning from Africa. Emerg Infect Dis. 2010;16:1608–10.
2.Malhotra U, Rakita R, Fernandez F, Harris G, Arguin P, Bronzan R, et al. Hepatitis temporally associated with an herbal supplement containing artemisinin—Washington, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:854–6.
3.Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
Figure
Figure. Bottle of artemisinin, available over-the-counter as an herbal supplement.

Suggested Citation for this Article
Rakita RM. Widespread availability of artemisinin monotherapy in the United States [letter]. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://www.cdc.gov/EID/content/17/5/954.htm

DOI: 10.3201/eid1705.101532


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Robert M. Rakita, University of Washington, 1959 NE Pacific, Box 356175 Seattle, WA 98195, USA; email: rakita@u.washington.edu


full-text:
Widespread Availability of Artemisinin Monotherapy in the United States | CDC EID

Yersinia pestis DNA Sequences | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011

Letter

Yersinia pestis DNA Sequences in Late Medieval Skeletal Finds, Bavaria

To the Editor: We read with interest the report by Wiechmann et al. that, in the investigation of late medieval plague, partial sequencing of the Yersinia pestis pPCP1 plasmid yielded the observation of a 3-T homopolymeric tract which differed from the 5-T homopolymeric tract of the Orientalis Y. pestis CO92 type strain (1). This observation was unexpected because previous data from multispacer sequence typing and glp D gene sequencing yielded only the Orientalis biotype in cases of ancient plague (2).

Using suicide PCR (3), we therefore further investigated pPCP1 in 10 negative control dental pulp specimens and 60 specimens collected from 1 Justinian Orientalis plague site (2), 2 Black Death Orientalis sites, and 2 additional medieval plague sites. All negative controls remained negative; 14 (23%) of 60 plague specimens yielded a PCR product, and 7 interpretable sequences yielded a 3-T homopolymeric tract in all cases.

We further tested a Y. pestis isolate collection comprising 2 Antiqua, 6 Medievalis, and 4 Orientalis strains. No amplification was obtained in DNA-free PCR mix and 5 Y. enterocolitica–negative control isolates, whereas sequencing yielded a 3-T homopolymeric tract in all 12 Y. pestis isolates.

BLAST analysis (http://blast.ncbi.nlm.nih.gov/blast.cgi) indicated that the 5-T homopolymeric tract has been found only once in the Y. pestis CO92 strain (4) and in none of 22 modern and 11 ancient sequences (Table). This 5-T homopolymeric tract is therefore CO92 strain specific and not a marker for the Orientalis biotype. This pPCP1 plasmid sequence, located into a noncoding region of the 3′ extremity of the plasmid, is characterized by several homopolymeric tracts of poly (A) and poly (T), including the 1 herein investigated. Instability of the T-stretches has been reported in bacterial genomes (5) as being hot spots for mutations (5).

Therefore, in our assessment, the data reported for the late medieval Bavaria burial (1) do not support that deaths of persons buried in this site resulted from a non-Orientalis plague. Typing modern or ancient Y. pestis strains should not rely on poly (A) and poly (T) homopolymeric tracts sequencing.

Acknowledgment
This study was funded by Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Unité Mixte de Recherche, Centre National de la Recherche Scientifique 6236.

Thi-Nguyen-Ny Tran, Didier Raoult, and Michel Drancourt
Author affiliation: Université de la Méditerranée, Marseille, France

Suggested citation for this article:
Tran T-N-N, Raoult D, Drancourt M. Yersinia pestis DNA sequences in late medieval skeletal finds, Bavaria [letter]. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://www.cdc.gov/EID/content/17/5/955.htm


full-text:
Yersinia pestis DNA Sequences | CDC EID


Comments to the Authors
Please contact the authors at the following addresses:

Michel Drancourt, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Unité de Mixte de Recherche, Centre National de la Recherche Scientifi que, 6236 –Institut de Recherche et de Développement 198, Faculté de Médecine, 27 Blvd Jean Moulin, 13385 Marseille CEDEX 5, France; email: michel.drancourt@univmed.fr

Ingrid Wiechmann, Ludwig Maximilian University of Munich, Department Biology I, Biodiversity research/Anthropology, Grosshaderner Str. 2, 82152 Planegg-Martinsried, Germany; email: i.wiechmann@lrz.uni-muenchen.de

Comparative effectiveness of white blood cell grow... [J Am Geriatr Soc. 2010] - PubMed result

J Am Geriatr Soc. 2010 Oct;58(10):1885-95. doi: 10.1111/j.1532-5415.2010.03081.x. Epub 2010 Sep 14.
Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL.
SourceDivision of Epidemiology and Disease Control, University of Texas School of Public Health, Houston, Texas, USA.

Abstract
OBJECTIVES: To determine the effect of colony-stimulating factor (CSF) on incidence of febrile neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma (NHL) treated with chemotherapy.

DESIGN: Retrospective cohort study.

SETTING: The Surveillance, Epidemiology, and End Results-Medicare database.

PARTICIPANTS: Thirteen thousand two hundred twenty-three people diagnosed with NHL at age 65 and older (mean age 74.9, range 65-102) in 1992 to 2002 who received chemotherapy within 12 months of diagnosis.

MEASUREMENTS: Primary prophylaxis was defined as CSF administered at the start of chemotherapy before febrile neutropenia or infection; secondary prophylaxis was defined as CSF use after febrile neutropenia or infection.

RESULTS: Participants with five to nine administrations of primary prophylactic CSF had a 42% lower risk of febrile neutropenia (odds ratio (OR)=0.58, 95% confidence interval (CI)=0.41-0.83), and participants with 10 or more administrations had a 48% lower risk (OR=0.52, 95% CI=0.36-0.76) after adjusting for age, stage, histology, and comorbidity. Results did not differ significantly after adjusting for propensity score of receiving CSF. There was no significant association between primary prophylactic CSF and overall survival, but secondary prophylactic CSF was significantly associated with better survival. Four to 10 administrations of secondary prophylactic CSF was associated with 9% lower mortality risk (hazard ratio (HR)=0.91, 95% CI=0.84-0.99), 11 to 23 administrations was associated with 23% lower mortality risk (HR=0.77, 95% CI=0.71-0.84) and 24 or more administrations was associated with 13% lower mortality risk (HR=0.87, 95% CI+0.79-0.95) than in participants not receiving CSF after neutropenia or infection.

CONCLUSION: Primary prophylactic CSF was observed to be effective in reducing the incidence of neutropenia and infection. These findings substantiate the clinical guidelines for recommending prophylactic CSF in older people with NHL receiving chemotherapy.

© 2010, Copyright the Authors. Journal compilation © 2010, The American Geriatrics Society.

PMID:20840455[PubMed - indexed for MEDLINE]
Comparative effectiveness of white blood cell grow... [J Am Geriatr Soc. 2010] - PubMed result

Hospital Survey on Patient Safety Culture: 2011 User Comparative Database Report

Hospital Survey on Patient Safety Culture
2011 User Comparative Database Report

--------------------

Based on data from 1,032 U.S. hospitals, the Hospital Survey on Patient Safety Culture: 2011 User Comparative Database Report provides initial results that hospitals can use to compare their patient safety culture to other U.S. hospitals. In addition, the 2011 report presents results showing change over time for 512 hospitals that submitted data more than once. The report consists of a narrative description of the findings and four appendixes, presenting data by hospital characteristics and respondent characteristics for the database hospitals overall and separately for the 512 trending hospitals.

Select to download print version (Part 1 [http://www.ahrq.gov/qual/hospsurvey11/hospsurv111.pdf], PDF File, 1.7 MB; Parts 2 and 3 [http://www.ahrq.gov/qual/hospsurvey11/hospsurv1123.pdf], PDF File, 1.6 MB). PDF Help.


--------------------

The Agency for Healthcare Research and Quality (AHRQ) released the Hospital Survey on Patient Safety Culture [Surveys on Patient Safety Culture], a tool to help hospitals evaluate how well they had established a culture of safety in their institutions, in 2004. A database was also needed so hospitals and units in hospitals could determine how well they were doing in establishing a culture of safety in comparison to other similar hospitals or hospital units.

The Hospital Survey on Patient Safety Culture: 2011 User Comparative Database Report meets that need. Based on data provided voluntarily by 1,032 U.S. hospitals, the Report provides results that hospitals can use as one basis for comparison in their efforts to establish, improve, and maintain a culture of patient safety in their institutions.

The main report presents statistics (averages, standard deviations, minimum and maximum scores and percentiles) on the patient safety culture areas or composites assessed in the survey as well as the survey items.

Appendixes A and B present breakouts of the data by hospital characteristics (bed size, teaching status, ownership and control, region) and respondent characteristics (hospital work area/unit, staff position, interaction with patients). Appendixes C and D show trends over time for the 512 hospitals that administered the survey and submitted data more than once. The average percent positive scores are shown for the composites and items, broken down by hospital characteristics (bed size, teaching status, ownership and control) and respondent characteristics (hospital work area/unit, staff position, interaction with patients).

Another round of voluntary data collection is planned to update the database with results from additional hospitals. Select for Hospital Comparative Database Submission Information [Hospital Comparative Database Submission Information].

Contents
Executive Summary
Purpose and Use of This Report
Chapter 1. Introduction
Chapter 2. Survey Administration Statistics
Chapter 3. Characteristics of Participating Hospitals
Chapter 4. Characteristics of Respondents
Chapter 5. Overall Results
Chapter 6. Comparing Your Results
Chapter 7. Trending: Comparing Results Over Time
Chapter 8. What's Next? Action Planning for Improvement
References
Notes: Description of Data Cleaning and Calculations
List of Tables
List of Charts

Appendixes A and B—Overall Results by Hospital and Respondent Characteristics
Appendix A: Overall Results by Hospital Characteristics
Appendix B: Overall Results by Respondent Characteristics

Appendix C and D—Trending Results by Hospital and Respondent Characteristics
Appendix C: Trending Results by Hospital Characteristics
Appendix D: Trending Results by Respondent Characteristics

Managed and prepared by: Westat, Rockville, MD under Contract No. HHSA 290200710024C.

Joann Sorra, Ph.D.
Theresa Famolaro, M.P.S.
Naomi Dyer, Ph.D.
Kabir Khanna, M.A.
Dawn Nelson

The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in this report.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without specific permission of copyright holders.

AHRQ Publication No. 11-0030
Current as of April 2011


---------------------
Internet Citation:

Sorra J, Famolaro T, Dyer N, et al. Hospital Survey on Patient Safety Culture: 2011 User Comparative Database Report. AHRQ Publication No. 11-0030, April 2011. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/qual/hospsurvey11/

---------------------
Hospital Survey on Patient Safety Culture: 2011 User Comparative Database Report

Risk of arrhythmic and nonarrhythmic death in pati... [Am Heart J. 2011] - PubMed result

Am Heart J. 2011 Jan;161(1):204-209.e1.

Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease.

Alsheikh-Ali AA, Trikalinos TA, Ruthazer R, Terrin N, Wong JB, Sarnak MJ, Estes NA 3rd, Kent DM.

Source
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. aalsheikhali@laum.mit.edu


Abstract
BACKGROUND: optimal utilization of therapies effective at preventing arrhythmic death but not nonarrhythmic death, for example, the implantable cardioverter-defibrillator (ICD), is challenging in patients with concomitant heart failure (HF) and chronic kidney disease (CKD), given the association of both conditions with competing risks of death.

OBJECTIVES: we examined the risk of arrhythmic and nonarrhythmic mortality in patients with different severities of HF and CKD.

METHODS: using individual patient data from the SOLVD, we categorized HF by New York Heart Association class and CKD severity by estimated glomerular filtration rate. Cox models with HF and CKD stages as time-dependent covariates were used to calculate hazard ratios for arrhythmic and nonarrhythmic death adjusted for age, gender, and enalapril allocation.

RESULTS: among 6,378 patients without an ICD (age 60 ± 10, left ventricular ejection fraction 27 ± 6, male 86%), there were 421 arrhythmic and 1188 nonarrhythmic deaths over a median follow-up of 34 months. Worse HF or CKD stages were associated with increased risk of both arrhythmic and nonarrhythmic death. The increase in the risk of nonarrhythmic death in the worst HF stage was disproportionately higher than that of arrhythmic death, and this disproportionate effect was more exaggerated in the presence of more advanced CKD.

CONCLUSION: while advanced CKD and HF stages are associated with increased risk of arrhythmic and nonarrhythmic death, benefits of ICDs in patients with more advanced disease may be limited by the preponderance of nonarrhythmic death.

PMID:21167355[PubMed - indexed for MEDLINE]
Risk of arrhythmic and nonarrhythmic death in pati... [Am Heart J. 2011] - PubMed result

Guidance for Industry: "Computer Crossmatch" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type)

Guidance for Industry: "Computer Crossmatch" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type)

[PDF Printable Version-78K]1
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM252894.pdf

Additional copies of this guidance are available from the Office of Communication, Outreach and Development (OCOD), (HFM-40), 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448, or by calling 1-800-835-4709 or 301-827-1800, or email ocod@fda.hhs.gov, or from the Internet at
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation
/Guidances/default.htm 2.

full-text:
Guidance for Industry: "Computer Crossmatch" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type)

Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease: Structured Abstract

Probiotics

Full Title: Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease
April 2011

View or download Report
http://www.ahrq.gov/downloads/pub/evidence/pdf/probiotics/probiotics.pdf
--------------------

Objectives: To catalog what is known about the safety of interventions containing Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and/or Bacillus strains used as probiotic agents in research to reduce the risk of, prevent, or treat disease.

Data Sources: We searched 12 electronic databases, references of included studies, and pertinent reviews for studies addressing the safety of probiotics from database inception to August 2010 without language restriction.

Review Methods: We identified intervention studies on probiotics that reported the presence or absence of adverse health outcomes in human participants, without restriction by study design, participant type, or clinical field. We investigated the quantity, quality, and nature of adverse events.

Results: The search identified 11,977 publications, of which 622 studies were included in the review. In 235 studies, only nonspecific safety statements were made ("well tolerated"); the remaining 387 studies reported the presence or absence of specific adverse events. Interventions and adverse events were poorly documented.

A number of case studies described fungemia and some bacteremia potentially associated with administered probiotic organisms. Controlled trials did not monitor routinely for such infections and primarily reported on gastrointestinal adverse events. Based on reported adverse events, randomized controlled trials (RCTs) showed no statistically significantly increased relative risk (RR) of the overall number of experienced adverse events (RR 1.00; 95% confidence interval [CI]: 0.93, 1.07, p=0.999); gastrointestinal; infections; or other adverse events, including serious adverse events (RR 1.06; 95% CI: 0.97, 1.16; p=0.201), associated with short-term probiotic use compared to control group participants; long-term effects are largely unknown. Existing studies primarily examined Lactobacillus alone or in combination with other genera, often Bifidobacterium.

Few studies directly compared the safety among different intervention or participant characteristics. Indirect comparisons indicated that effects of delivery vehicles (e.g., yogurt, dairy) should be investigated further. Case studies suggested that participants with compromised health are most likely to experience adverse events associated with probiotics. However, RCTs in medium-risk and critically ill participants did not report a statistically significantly increased risk of adverse events compared to control group participants.

Conclusions: There is a lack of assessment and systematic reporting of adverse events in probiotic intervention studies, and interventions are poorly documented. The available evidence in RCTs does not indicate an increased risk; however, rare adverse events are difficult to assess, and despite the substantial number of publications, the current literature is not well equipped to answer questions on the safety of probiotic interventions with confidence.


--------------------
Download Report
Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease

•Executive Summary: Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease: Summary of Evidence Report/Technology Assessment, No. 200 (Publication No. 11-E007-1)


•Evidence Report (Publication No. 11-E007-EF): (PDF File, 8.4 MB, 645 pages) PDF Help
http://www.ahrq.gov/downloads/pub/evidence/pdf/probiotics/probiotics.pdf

Evidence-based Practice Center: RAND-Southern California
Topic Nominators: National Institutes of Health (NIH) Office of Dietary Supplements; NIH National Center for Complementary and Alternative Medicine; Food and Drug Administration, Center for Food Safety and Applied Nutrition

Current as of April 2011


------------------
Internet Citation:

Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease, Structured Abstract. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/tp/probiotictp.htm

----------------
Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease: Structured Abstract

A. phagocytophilum Infection in Ticks | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011
Letter
Anaplasma phagocytophilum Infection in Ticks, China–Russia Border
Jia-Fu Jiang, Bao-Gui Jiang, Ji-Hong Yu, Wen-Yi Zhang, Hong-Wei Gao, Lin Zhan, Yi Sun, Xiao-Ai Zhang, Pan-He Zhang, Wei Liu, Xiao-Ming Wu, Rong-Man Xu, and Wu-Chun Cao

Author affiliations: State Key Laboratory of Pathogen and Biosecurity, Beijing, People's Republic of China; and Institute of Microbiology and Epidemiology, Beijing


Suggested citation for this article


To the Editor: Anaplasma phagocytophilum, an emerging human pathogen of public health importance, is transmitted to humans most commonly by tick bites (1). The agent has been detected in various species of Ixodes ticks around the world (2) and in Dermacentor silvarum ticks in northeastern People's Republic of China (3), where 3 A. phagocytophilum strains were isolated from wild and domestic animals (4). In the Asiatic region of Russia adjacent to China, A. phagocytophilum was identified in Ixodes persulcatus ticks, and A. bovis in Haemaphysalis concinna ticks (5). Human granulocytic anaplasmosis was reported in the southern area of the Russian Far East that borders China (6). The objectives of this study were to investigate the prevalence of A. phagocytophilum in ticks collected from the China–Russia border and to characterize the agent by molecular biology techniques.

During May–June 2009, host-seeking ticks were collected by flagging vegetation of grassland or woodland along the China–Russia border. Attached ticks were collected from sheep and goats in Hunchun, and from dogs in Suifenhe (Table). All ticks were identified by morphologic features to the species level and the developmental stage by 2 entomologists (Y. Sun and R.-M. Xu). DNA was extracted from tick samples by using Tissue DNA Extract kit (Tiangen Biotechnique Inc., Beijing, China), following the instructions of the manufacturer. Nested PCR was performed to amplify partial citrate synthase gene (gltA) of A. phagocytophilum as previously described (7). To avoid possible contamination, DNA extraction, the reagent setup, amplification, and agarose gel electrophoresis were performed in separate rooms, and negative control samples (distilled water) were included in each amplification.

A. phagocytophilum was detected in 83 of 2,429 adult ticks, with an overall prevalence of 3.42% (Table). The infection rates in the 14 survey sites ranged from 0 to 5.96%, and were significantly different (χ2 = 24.43, df = 13; p = 0.027). Except for H. japonica, ticks from 4 species, including H. concinna, H. longicornis, I. persulcatus, and D. silvarum were found to be naturally infected. The difference in infection rates among tick species was statistically significant (χ2 = 13.03, df = 4; p = 0.011). Of 367 attached H. longicornis ticks obtained from domestic animals in Hunchun and Suifenhe, 12 (3.27%) were infected with A. phagocytophilum (Table). Nymphal ticks were only collected from vegetation in Hunchun, and 30 pools (10 in each pool) of 1,190 H. concinna nymphs were positive with an estimated minimum prevalence of 2.52%.

full-text:
A. phagocytophilum Infection in Ticks | CDC EID


Suggested Citation for this Article
Jiang J-F, Jiang B-G, Yu J-H, Zhang W-Y, Gao H-W, Zhan L, et al. Anaplasma phagocytophilum infection in ticks, China–Russia border [letter]. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://www.cdc.gov/EID/content/17/5/932.htm


DOI: 10.3201/eid1705.101630


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Wu-Chun Cao, Beijing Institute of Microbiology and Epidemiology, China, Department of Epidemiology, 20 Dongda St, FengTai District, Beijing 100071, People's Republic of China; email: caowc@nic.bmi.ac.cn

The Crab Hole Mosquito Blues | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011
Another Dimension
The Crab Hole Mosquito Blues
Karl M. Johnson, Douglas F. Antczak, William H. Dietz, David H. Martin, and Thomas E. Walton

Author affiliations: Retired (K.M. Johnson, T.E. Walton); Cornell University, Ithaca, New York, USA (D.F. Antczak); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.H. Dietz); and Louisiana State University Health Science Center, New Orleans, Louisiana, USA (D.H. Martin)

Suggested citation for this article

Abstract
Venezuelan equine encephalomyelitis (VEE) epizoodemics were reported at 6–10-year intervals in northern South America beginning in the 1920s. In 1937, epizootic VEE virus was isolated from infected horse brain and shown as distinct from the North American equine encephalomyelitis viruses. Subsequently, epizootic and sylvatic strains were isolated in distinct ecosystems; isolates were characterized serologically as epizootic subtype I, variants A/B and C; or sylvatic (enzootic) subtype I, variants D, E, and F, and subtypes II, III, and IV. In 1969, variant I-A/B virus was transported from a major outbreak in northern South America to the borders of El Salvador, Guatemala, and Honduras. This musical poem describes the history and ecology of VEE viruses and the epidemiology of an unprecedented 1969 movement of VEE viruses from South America to equids and humans in Central America from Costa Rica to Guatemala and Belize and in Mexico and the United States that continued until 1972.


full-text:
The Crab Hole Mosquito Blues | CDC EID


Suggested Citation for this Article
Johnson KM, Antczak DF, Dietz WH, Martin DH, Walton TE. The Crab Hole Mosquito Blues [another dimension]. Emerg Infect Dis [serial on the Internet]. 2011 May [date cited]. http://www.cdc.gov/EID/content/17/5/923.htm


DOI: 10.3201/eid1705.101412


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Thomas E. Walton, 5365 North Scottsdale Rd, Eloy, AZ 85131-3507, USA; email: tewalton@q.com

Tick-Borne Encephalitis Virus, Kyrgyzstan | CDC EID

EID Journal Home > Volume 17, Number 5–May 2011

Volume 17, Number 5–May 2011
Dispatch
Tick-Borne Encephalitis Virus, Kyrgyzstan
Benjamin J. Briggs, Barry Atkinson, Donna M. Czechowski, Peter A. Larsen, Heather N. Meeks, Juan P. Carrera, Ryan M. Duplechin, Roger Hewson, Asankadyr T. Junushov, Olga N. Gavrilova, Irena Breininger, Carleton J. Phillips, Robert J. Baker, and John Hay

Author affiliations: State University of New York, Buffalo, New York, USA (B.J. Briggs, D.M. Czechowski, J. Hay); Health Protection Agency, Porton Down, Salisbury, UK (B. Atkinson, R. Hewson); Texas Tech University, Lubbock, Texas, USA (P.A. Larsen, H.N. Meeks, J.P. Carrera, R.M. Duplechin, C.J. Phillips, R.J. Baker); National Academy of Sciences of the Kyrgyz Republic, Bishkek, Kyrgyz Republic (A.T. Junushov); and Ministry of Healthcare of the Kyrgyz Republic, Bishkek (O.N. Gavrilova, I. Breininger)

Suggested citation for this article

Abstract
Tick-borne encephalitis virus (TBEV) is an emerging pathogen in Europe and Asia. We investigated TBEV in Kyrgyzstan by collecting small mammals and ticks from diverse localities and analyzing them for evidence of TBEV infection. We found TBEV circulating in Kyrgyzstan much farther south and at higher altitudes than previously reported.

Tick-borne encephalitis virus (TBEV) is a flavivirus in the family Flaviviridae. The TBEV positive-sense RNA genome is translated as a polyprotein and subsequently cleaved into 3 structural and 7 nonstructural (NS) proteins (1). TBEV has 3 subtypes— European, Siberian, and Far-Eastern—each of which has its own ecology, clinical presentation, and geographic distribution (2). The vectors are Ixodes ricinus ticks for the European subtype and I. persulcatus ticks for the other 2 subtypes. TBEV circulates through a complex cycle involving small mammals, ticks, and large mammals (3); it can also be transmitted through consumption of unpasteurized milk and milk products (4).

Our unpublished data and that of others suggest that TBEV circulates in Kazakhstan. However, we have found no reports (in English) since 1978 of TBEV infection in the neighboring Kyrgyz Republic (Kyrgyzstan). Kyrgyzstan has extensive alpine and subalpine habitats (94% of Kyrgyzstan is >1,000 m above sea level) (5); the Tien Shan mountain range dominates and physiographically links Kyrgyzstan to the Himalayas and western People's Republic of China. We conducted fieldwork in Kyrgyzstan during June–July 2007 and July–August 2009 to establish a baseline of risk for zoonotic diseases, including TBEV.

full-text:
Tick-Borne Encephalitis Virus, Kyrgyzstan | CDC EID


Suggested Citation for this Article
Briggs BJ, Atkinson B, Czechowski DM, Larsen PA, Meeks HN, Carrera JP, et al. Tick-borne encephalitis virus, Kyrgyzstan. Emerg Infect Dis [serial onthe Internet]. 2011 Mar [date cited].
http://www.cdc.gov/EID/content/17/3/876.htm


DOI: 10.3201/eid1705.101183


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Benjamin J. Briggs, 606 BRB, State University of New York, South Campus, 3435 Main St, Buffalo, NY 14214, USA; email: bjbriggs@buffalo.edu